里昂发表报告，预计京东健康(06618.HK) 今年首季关键绩效指标表现稳健，估计总收入料按年升15%至153亿元人民币，主要受惠1月以来流感爆发带动的药品需求增加，以及京东平台因以旧换新优惠政策改善的用户流量。该行料季内药品销售将按年升20%，保健品和医疗器械销售或能保持10%以上按年增长。经调整除息税前溢利料按年升15%，利润率稳定在5.7%。
该行料公司上半年总收入按年升14%，意味第二季度按年13%，该行维持对公司今年15%按年收入增长和6.6%的净利润率预测。里昂重申京东健康“跑赢大市”评级及目标价45元。(fc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-12 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.